1. Home
  2. ATAI vs ARDX Comparison

ATAI vs ARDX Comparison

Compare ATAI & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$3.38

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.54

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATAI
ARDX
Founded
2018
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ATAI
ARDX
Price
$3.38
$5.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$15.13
$15.14
AVG Volume (30 Days)
4.4M
2.8M
Earning Date
03-06-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$308,000.00
$2,607,000.00
Revenue This Year
N/A
$37.75
Revenue Next Year
N/A
$34.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.15
$3.50
52 Week High
$6.73
$8.40

Technical Indicators

Market Signals
Indicator
ATAI
ARDX
Relative Strength Index (RSI) 41.37 39.82
Support Level $3.06 $5.49
Resistance Level $4.30 $6.63
Average True Range (ATR) 0.21 0.24
MACD -0.03 0.02
Stochastic Oscillator 13.33 52.36

Price Performance

Historical Comparison
ATAI
ARDX

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: